Arax Advisory Partners’s Castle Biosciences CSTL Stock Holding History

Arax Advisory Partners’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$99	Sell	4 -33	-89%	-$1.08K	﹤0.01%	3615
2025 Q4	$1.44K	Sell	37 -537	-94%	-$17.3K	﹤0.01%	3381
2025 Q3	$13.1K	Buy	+574	New	+$11.7K	﹤0.01%	2483
2025 Q1	–	Sell	-31	Closed	-$827	–	2751
2024 Q4	$827	Hold	31	–	–	﹤0.01%	2211
2024 Q3	$885	Hold	31	–	–	﹤0.01%	2293
2024 Q2	$675	Buy	+31	New	+$691	﹤0.01%	2278
2023 Q4	–	Sell	-12	Closed	-$203	–	1354
2023 Q3	$203	Hold	12	–	–	﹤0.01%	1282
2023 Q2	$165	Hold	12	–	–	﹤0.01%	1240
2023 Q1	$273	Hold	12	–	–	﹤0.01%	1232
2022 Q4	$282	Buy	+12	New	+$278	﹤0.01%	1224
2022 Q2	–	Sell	-12	Closed	-$1K	–	1173
2022 Q1	$1K	Hold	12	–	–	﹤0.01%	1015
2021 Q4	$1K	Buy	+12	New	+$627	﹤0.01%	988

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's CSTL Position: Q1 2026 in Review

Arax Advisory Partners reduced its Castle Biosciences (CSTL) stake by 89% in Q1 2026, selling an estimated $1.08K and leaving 4 shares worth $99. The position accounts for ﹤0.01% of the portfolio, ranked #3615.

Arax Advisory Partners first reported a position in CSTL in Q4 2021 and has held it in 12 quarters since. The position peaked at $13.1K in Q3 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

Arax Advisory Partners held 4 shares of Castle Biosciences worth $99 as of Q1 2026.
Arax Advisory Partners sold 33 Castle Biosciences shares in Q1 2026, an estimated $1.08K.
Castle Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3615 holding.
Arax Advisory Partners first reported a position in Castle Biosciences in Q4 2021 and has held it in 12 quarters since.
Arax Advisory Partners's Castle Biosciences position peaked at $13.1K in Q3 2025.
186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.